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Abstract
We collected a series of 136 lung/bronchial and 56 matched lung parenchyma tissue samples from patients who underwent
lung/bronchial biopsies and presented invasive carcinoma after lung surgery. The lung/bronchial samples included basal cell
hyperplasia, squamous metaplasia, moderate dysplasia, adenomatous hyperplasia, severe dysplasia, squamous cell
carcinoma and adenocarcinoma. Matched lung parenchyma tissue samples included 25 squamous cell carcinomas and
31 adenocarcinomas. Immunohistochemistry was performed to analyze for the distribution of hyaluronidase (Hyal)-1 and -3,
and hyaluronan synthases (HAS)-1, -2, and -3. Hyal-1 showed signiﬁcantly higher expression in basal cell hyperplasia than in
moderate dysplasia (P=0.01), atypical adenomatous hyperplasia (P=0.0001), or severe dysplasia (P=0.03). Lower expression
of Hyal-3 was found in atypical adenomatous hyperplasia than in basal cell hyperplasia (P=0.01) or moderate dysplasia
(P=0.02). HAS-2 was signiﬁcantly higher in severe dysplasia (P=0.002) and in squamous metaplasia (P=0.04) compared with
basal cell hyperplasia. HAS-3 was signiﬁcantly expressed in basal cell hyperplasia compared with atypical adenomatous
hyperplasia (P=0.05) and severe dysplasia (P=0.02). Lower expression of HAS-3 was found in severe dysplasia compared with
squamous metaplasia (P=0.01) and moderate dysplasia (P=0.01). Epithelial Hyal-1 and -3 and HAS-1, -2, and -3 expressions
were signiﬁcantly higher in pre-neoplastic lesions than in neoplastic lesions. Comparative Cox multivariate analysis controlled
by N stage and histologic tumor type showed that patients with high HAS-3 expression in pre-neoplastic cells obtained by lung/
bronchial biopsy presented a signiﬁcantly higher risk of death (HR=1.19; P=0.04). We concluded that localization of Hyal and
HAS in lung/bronchial pre-neoplastic and neoplastic lesions was inversely related to malignancy, which implied that visualizing
these factors could be a useful diagnostic procedure for suspected lung cancer. Finalizing this conclusion will require a wider
study in a randomized and prospective trial.
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chemistry; Morphometry; Prognosis
Introduction
Lung cancer remains the leading cause of cancer
death worldwide. At the time of diagnosis, lung cancer is
usually extensive, and despite improvements in therapy,
the overall 5-year survival rate for lung cancer patients
remains less than 15% (1). The major reasons for the poor
prognosis for lung cancer are the lack of effective
screening and early diagnosis procedures, the propensity
for early metastasis and the inability of systemic therapies
to cure patients with widely metastatic disease (2).
Lung cancer is the result of a multi-step accumulation
of genetic and/or epigenetic alterations. Better under-
standing of the molecular mechanisms by which these
alterations affect lung cancer pathogenesis could provide
new diagnostic procedures and prognostic factors for
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detection of early-stage or recurrent disease. In this
regard, many have investigated molecular markers in
pre-neoplastic and neoplastic lesions to gain insight into
tumor recurrence and shortened survival (3). Because
degradation of the extracellular matrix is important to
invasion, cellular motility, and proliferation, several glycos-
aminoglycans have been targeted as potentially useful
tumor markers. Among these, hyaluronidases (Hyal) and
hyaluronan synthases (HAS) have shown to be promising
markers. Increased hyaluronidase expression has also
been reported in colon (4,5), prostate (6), ovarian (7)
endometrium (8), breast (9,10), skin (11), and lung (12–14)
cancers. HAS is a group of isozymes that synthesizes
hyaluronan (HA), a glycosaminoglycan abundant in con-
nective tissue and also present in several types of epithelia
(15,16) where it controls cell migration, differentiation and
proliferation (17). Three types of HAS are known: HAS-1,
HAS-2, and HAS-3 (18). Therefore, upregulated HAS
expression is a likely contributor to HA accumulation in
tissues, and promotes tumor growth (4) and metastasis,
especially when co-expressed with Hyal (19). Different
types of Hyal – Hyal-1, Hyal-2, and Hyal-3 – can degrade
the long chains of alternating units of N-acetylglucosamine
and glucuronic acid into different-sized molecules. Hyal
degrades HA into fragments of 20-25 disaccharides, which
are needed to activate the MAP-kinase pathway (20). The
major mRNA transcript of Hyal-3 is enzymatically inactive
and appears to have only a supportive role in Hyal-1
expression (21).
Expression of epithelial HA, Hyal, and HAS is modu-
lated in premalignant and malignant esophageal, breast,
ovarian, and lung tumors (22–24). We hypothesized that
Hyal and HAS expressions also change in bronchial
metaplasia and dysplasia, and in atypical adenomatous
hyperplasia, which are thought to be stages in the
development of squamous cell lung carcinoma (25,26)
and adenocarcinoma, respectively. To test this hypothesis,
we collected samples of metaplastic, dysplastic, and
atypical adenomatous hyperplasia lesions and malignant
lung tumors and stained them for Hyal and HAS.
Material and Methods
Histologic specimens
We retrospectively obtained 136 lung specimens of
pre-neoplastic lesions from endoscopic biopsies and lung
resections removed from 56 patients who were diagnosed
with lung cancer and had undergone diagnostic and/or
surgical treatment. Endoscopic biopsies or lung resec-
tions were performed under general anesthesia in the
Hospital das Clínicas, AC Camargo Cancer Center,
University of Coimbra, and Brompton Hospital in London,
from 2008 to 2011. For endoscopic biopsies, a ﬂexible
bronchoscope (model 1Q10, Olympus Corp., Japan) was
used. The bronchoscope was directly used at sites of
nodules or masses. Typically, three or more samples
were obtained. After this procedure, specimens were
ﬁxed in 10% buffered formalin for periods of 4-16 h and
embedded in parafﬁn according to the routine of the
laboratory involved. Staining by hematoxylin and eosin,
and mucicarmine or PAS with diastase was performed
on 5-mm sections in all specimens embedded in parafﬁn
and reviewed by two pathologists (VKS and VLC).
Slides resulting from the processing of each specimen
were obtained from the pathology ﬁles of each institu-
tion for review and revision. The 2015 World Health
Organization lung tumor classiﬁcation (27) was used to
classify basal cell hyperplasia (n=64), squamous
metaplasia (n=13), moderate dysplasia (n=14), severe
dysplasia (n=9), and atypical adenomatous hyperplasia
(n=36). The invasive carcinomas consisted of 25
squamous cell carcinomas, and 31 adenocarcinomas.
For evaluation of staining coverage and intensity, the
tissue sections were stained for HAS-1, -2, and -3 and
Hyal-1, -2, and -3 as described below. Table 1 summarizes
the patient characteristics.
The project was approved by the Ethics Committee for
Research Project Analysis (CAPPesq) from the Diretoria
Clínica do Hospital das Clínicas and Faculdade de
Medicina, Universidade de São Paulo, São Paulo, SP,
Brazil.
Table 1. Patient characteristics.
Characteristics n=56
Median age, years (range) 64 (43–84)
Gender
Male 35
Female 21
Median tobacco history, pack/years (range) 37 (0–100)
Overall stage
I 36
II 16
III 4
N stage
N0 42
N1 14
Treatment
Surgery 56
Surgery+chemotherapy 4
Histological types
Squamous cell carcinoma 25
Adenocarcinoma 31
Median follow-up, months (range) 16 (3–30)
Patients censored for survival analysis at last
follow-up time
18
Data are reported as number of the 56 patients out of 136 who
underwent lung/bronchial biopsies and presented invasive
carcinoma after lung surgery.
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HAS and Hyal staining
To avoid antigen decay, serial slide sections from
formalin-ﬁxed parafﬁn-embedded (FFPE) tissues were
parafﬁn coated and stored at 4°C during a median period
of 4 years (i.e., from 2008 to 2011) in the different centers
included in the study.
Immunohistochemistry was performed to detect Hyal-1, -3
and HAS-1-3 antigens in pre-neoplastic and neoplastic
lesions, using monoclonal antibody Hyal-1 (1D10), Hyal-3
(E-11), HAS-1 (C-14), HAS-2 (S-15), and HAS-3 (E-15), all
from Santa Cruz Biotechnology (USA). Brieﬂy, silanized
slides containing tissue sections of 3 mm were used in all
cases. The sections were deparafﬁnized in xylol, rehy-
drated in an alcohol gradient, and stored in 0.05 M sodium
phosphate buffer (PBS), pH 7.2–7.4. The sections were
then subjected to antigen retrieval in a microwave oven.
Next, the slides were incubated overnight with the
respective antibodies in concentrations previously estab-
lished (1:200), washed in 0.05 M PBS, pH 7.2–7.4, and
incubated with the secondary antibody, using a large
streptavidin-avidin-biotin-peroxidase system (k-0690; Dako
A/S, Denmark). Diaminobenzidine (Sigma Diagnostics,
USA) was used as a chromogen, and the sections
counterstained with hematoxylin. Intense brown cytoplas-
mic staining in pre-neoplastic and neoplastic lesions was
considered positive for Hyal-1 and -3 and HAS-1-3.
Evaluation of immunostaining
After the immunohistochemical reaction, markers in
tumors and pre-neoplastic lesions were quantiﬁed using
the Automated Cellular Imaging System (ACIS) III instru-
ment (Dako, USA). Brieﬂy, ACIS III consists of an
automated digital microscope and a computer with a
26-image capture and image processing system. Each
immunohistochemically stained slide was scanned and
the images were reviewed on the computer screen. The
ACIS III can detect, count and classify cell types based on
levels of hue, saturation and brightness. The signal is then
converted to number density measurement. The computer
software ‘‘membranes and cytoplasm’’, which is part of
the system, was used to analyze protein expression by
measuring the staining intensity of the cytoplasm and cell
membranes and adjusting the threshold to the pixels
showing immunoreactivity or not. The results are reported
in continuous variables ranging from 0 to 256. The areas
to be analyzed on each slide were selected manually
using the selection tools of the ACIS III. For statistical
analyses, we used the average of two regions (stroma and
tumor) of each case (24).
Statistical analysis
Statistical analysis was performed using PASW Statistics
for Windows, Version 18.0 (SPSS Inc., USA). When
necessary, variables were analyzed with the Kolmogorov-
Smirnov test to determine the normality pattern. ANOVA
tests were used to analyze Hyal-1 and -3 and HAS-1-3
immunoexpression in pre-neoplastic and neoplastic lesions.
When non-parametric methods were used, simultaneous
comparisons of conﬁdence were corrected with Bonferroni’s
posttest. The Spearman test was used to clarify relationships
between Hyal-1 and -3 and HAS-1, -2, and -3 staining with
pre-neoplastic variables studied. Receiver operation char-
acteristic (ROC) curves were developed to determine
optimal cut-off limits that yielded the best possible sensitivity
and speciﬁcity values. Data on surgical and pathologic
parameters, and Hyal and HAS staining inferences, were
analyzed by the Cox proportional hazards model, using
single-variable analysis (univariate analysis). Stratiﬁed
Kaplan-Meier analyses were performed on the variables
found to be signiﬁcant in the multivariate Cox proportional
hazards model. Results for which Pp0.05 were considered
to be signiﬁcant.
Results
Cells showing Hyal-1- or Hyal-3-positive immunostain-
ing were mainly epithelial cells, whereas most stromal
cells showed negative or weak expression (Figure 1).
Hyaluronidase-positive staining was localized intracellu-
larly, spreading diffusely throughout the cytoplasm
(Figure 2). Immunostaining with speciﬁc antibodies for
HAS-1-3 showed positive staining in all samples, regard-
less of the lesion type (Figure 2). The HAS-1-3 proteins
were detected homogenously in the cytoplasm and at the
plasma membrane (Figure 2).
In all tissue groups, Hyal-1-positive epithelial cells
ranged from 15.81± 11.16 to 82.56 ± 11.96 (Table 2).
The percentage of Hyal-1 was signiﬁcantly higher in basal
cell hyperplasia compared with moderate dysplasia
(P=0.02), adenomatous hyperplasia (P=0.0001), severe
dysplasia (P=0.05), squamous cell carcinoma (P=0.0001),
and adenocarcinoma (P=0.0001; Figure 3A). Adenoma-
tous hyperplasia expressed less Hyal-1 than did squa-
mous metaplasia (P=0.004), squamous cell carcinoma
(Po0.01) or adenocarcinoma (Po0.01; Figure 3A). The
percentage of Hyal-3-positive epithelial cells ranged from
47.90 ± 22.41% to 79.49 ± 23.51 (Table 2). Hyal-3
staining intensity in epithelial cells was weak in atypical
adenomatous hyperplasia, moderate in basal cell hyper-
plasia and strong in moderate hyperplasia (Figure 3B).
The percentage of positive cells in the pre-neoplastic
lesions and tumor cells also differed among the HAS
isoforms (Table 2; Figures 2 and 3C). The proportion of
HAS-1-positive epithelial cells tended to be signiﬁcantly
lower in squamous cell carcinoma and adenocarcinomas
than in pre-neoplastic lesions (P=0.05; Figure 3C). HAS-1
percentage in basal cell hyperplasia was 63.14 ± 20.18
whereas average HAS-1-positive cell percentages in
other pre-neoplastic lesions were squamous metaplasia:
64.84± 16.60; moderate dysplasia: 66.32± 13.96; atypical
adenomatous hyperplasia: 46.63 ± 31.81; and severe
dysplasia: 51.61 ± 22.54 (Po0.05). For squamous cell
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Figure 2. Hyaluronan synthases (HAS)-1, -2, and -3 in basal
cell hyperplasia, squamous metaplasia, moderate dysplasia,
atypical adenomatous hyperplasia, severe dysplasia, squa-
mous cell carcinoma and adenocarcinoma, shown by immu-
nohistochemistry staining. Similar expression of HAS-1 was
seen in basal cell hyperplasia, squamous metaplasia, moder-
ate dysplasia, atypical adenomatous hyperplasia and severe
dysplasia. Fewer epithelial cells in squamous cell carcinoma
and adenocarcinoma expressed HAS-1. Numerous epithelial
cells expressed HAS-2 in severe dysplasia compared to basal
cell hyperplasia, squamous metaplasia and basal cell hyper-
plasia. HAS-3 was prominently expressed in basal cell
hyperplasia, atypical adenomatous hyperplasia and severe
dysplasia. Few epithelial cells expressed HAS-3 in severe dys-
plasia compared to squamous metaplasia and moderate dyspla-
sia. Arrows and asterisks indicate cytoplasmic expression in
epithelial cells of pre-neoplastic and neoplastic tissue. Bar:
100 mm.
Figure 1. Hyaluronidase (Hyal)-1 and -3 in basal cell hyperplasia,
squamous metaplasia, moderate dysplasia, atypical adenoma-
tous hyperplasia, severe dysplasia, squamous cell carcinoma and
adenocarcinoma, as shown by immunohistochemistry staining.
Hyal-1 was more prominently expressed by epithelial cells in
basal cell hyperplasia than in moderate dysplasia, adenomatous
hyperplasia, severe dysplasia, squamous cell carcinoma or
adenocarcinoma. Hyal-1 expression decreased and became
more dispersed as malignancy increased and epithelial cells
became less organized. Strong and diffuse expression of Hyal-3
was seen in atypical adenomatous hyperplasia, basal cell
hyperplasia and moderate dysplasia. Arrows and asterisks
indicate cytoplasmic expression in epithelial cells of pre-neoplas-
tic and neoplastic tissue. Bar: 100 mm.
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carcinoma and adenocarcinoma, the proportion of HAS-1-
positive cells was typically less than 20 (P=0.0001;
Figure 3C). Staining of HAS-2 was signiﬁcantly higher in
severe dysplasia (P=0.002) and squamous metaplasia
(P=0.01) than basal cell hyperplasia (Figure 3D). HAS-3
showed signiﬁcantly greater expression in basal cell
hyperplasia than in atypical adenomatous hyperplasia
(Po0.05) or severe dysplasia (Po0.05; Figure 3E). Lower
HAS-3 expression was found in severe dysplasia than in
squamous metaplasia (Po0.01) or moderate dysplasia
(Po0.01; Figure 3E).
Table 3 shows correlation analyses for Hyal-1 and -3,
and HAS-1, -2, and -3 expression and lesion types. A
signiﬁcant direct association was found between Hyal-1
and HAS-1 (R=0.40; P=0.0001), HAS-2 (R=0.40.
P=0.0001) and HAS-3 (R=0.50; P=0.0001). Pre-neoplas-
tic and tumor lesions showed inverse associations
between Hyal-1 (R=–0.70; P=0.0001), HAS-1 (R=–0.30;
P=0.03), HAS-3 (R=–0.45; P=0.0001).
Comparative Cox multivariate analyses by N stage
and tumor histology showed a signiﬁcant association
between poor survival and high pre-neoplastic cell HAS-3
levels (HR=1.19; P=0.04; Table 4). We ranked the cases
by ROC curve into two groups with distinctly different
average survival times as illustrated by regression plots in
Figure 4. The group with o27.01% HAS-3 had a median
survival time of 72 months, whereas those with427.01%
HAS-3 had a median survival time of just 52 months after
surgery.
Discussion
For the present study, we hypothesized that in pre-
neoplastic lesions, and squamous cell carcinoma and
adenocarcinoma subtypes – i.e., tumors with different
behaviors – Hyal and HAS should modulate different
malignancy-induced pathways that affect lung cancer
carcinogenesis. By IHC staining, we found that Hyal-1
and -3, and HAS-1-3 were signiﬁcantly overexpressed by
epithelial cells in pre-neoplastic lesions compared with
tumor epithelial cells. In fact, heterogeneous hyaluroni-
dase expression has been shown in malignancies, and
shows promise as an indicator of disease progression.
Antigen decay in archival formalin-ﬁxed parafﬁn-
embedded (FFPE) tissue sections for immunohistochemistry
Table 2. Distribution and staining intensity of Hyal-1 and -3 and
HAS-1, -2 and -3 in pre-neoplastic and neoplastic epithelium.
Protein/lesion Means±SD
Hyaluronidase 1
Basal cell hyperplasia 82.56±11.96
Squamous metaplasia 58.31±23.26
Moderate dysplasia 36.09±27.30
Adenomatous hyperplasia 15.81±11.16
Severe dysplasia 43.01±27.04
Squamous cell carcinoma 29.90±15.04
Adenocarcinoma 35.43±16.34
Hyaluronidase 3
Basal cell hyperplasia 67.88±23.41
Squamous metaplasia 71.87±29.54
Moderate dysplasia 79.49±23.51
Adenomatous hyperplasia 47.90±22.41
Severe dysplasia 68.00±27.46
Squamous cell carcinoma 56.80±31.19
Adenocarcinoma 56.47±27.01
Hyaluronan synthase 1
Basal cell hyperplasia 63.14±20.81
Squamous metaplasia 64.84±16.60
Moderate dysplasia 66.32±13.96
Adenomatous hyperplasia 46.63±31.81
Severe dysplasia 51.61±22.54
Squamous cell carcinoma 21.78±17.15
Adenocarcinoma 28.31±21.33
Hyaluronan synthase 2
Basal cell hyperplasia 73.08±19.57
Squamous metaplasia 83.45±7.53
Moderate dysplasia 75.73±18.25
Adenomatous hyperplasia 66.27±28.32
Severe dysplasia 91.13±8.60
Squamous cell carcinoma 17.69±17.44
Adenocarcinoma 19.87±18.17
Hyaluronan synthase 3
Basal cell hyperplasia 73.67±21.06
Squamous metaplasia 66.72±29.87
Moderate dysplasia 65.57±18.76
Adenomatous hyperplasia 39.28±30.07
Severe dysplasia 27.02±26.08
Squamous cell carcinoma 9.51 ±10.79
Adenocarcinoma 10.34±10.19
Data are reported as means±SD. Determination of Hyal and
HAS expression was based on immunohistochemistry. Hyal-1
expression was signiﬁcantly greater in basal cell hyperplasia
than moderate dysplasia (P=0.02), adenomatous hyperplasia
(P=0.0001), severe dysplasia (P=0.05), squamous cell carcinoma
(P=0.0001) or adenocarcinoma (P=0.0001). Adenomatous hyper-
plasia expressed less Hyal-1 than did squamous metaplasia
(P=0.004), squamous cell carcinoma (Po0.01) or adenocarci-
noma (Po0.01). Hyal-3 staining in epithelial cells signiﬁcantly
differed between atypical adenomatous hyperplasia and basal
cell hyperplasia (P=0.01) and moderate dysplasia (P=0.02).
Squamous cell carcinoma and adenocarcinoma show lower
proportions of HAS-1-positive cells than do pre-neoplastic lesions
(P=0.0001). HAS-2 expression was signiﬁcantly higher in severe
dysplasia (P=0.002) and in squamous metaplasia (P=0.01) than
in basal cell hyperplasia. HAS-3 was signiﬁcantly higher in basal
cell hyperplasia than atypical adenomatous hyperplasia (Po0.05)
and severe dysplasia (Po0.05). HAS-3 expression was lower in
severe dysplasia than in squamous metaplasia (Po0.01) or in
moderate dysplasia (Po0.01). The independent samples t-test
was used for statistical analysis.
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Figure 3. Intensity and coverage of Hyal-1 and -3 and HAS-1, -2, and -3 staining in pre-neoplastic, squamous cell carcinoma and
adenocarcinoma. See Results section for complete information about statistical comparisons (ANOVA).
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stored at room temperature is a well-known phenomenon
which may have affect translational and research studies;
length of storage time appears central to this problem
(28,29). In the present study, this phenomenon had been
previously minimized in the different centers where the
samples were obtained for our study, as the serial slide
sections from FFPE tissues were parafﬁn coated and cold
stored at 4°C for a median time period of 4 years (i.e., from
2008 to 2011). Additionally, antigens that are nuclear or
membranous (e.g., CD3, CD 31, CD117, estrogen and
progesterone receptors, Ki67, p53, TTF-1, vimentin) show
reduced immunosignals, whereas cytoplasmic antigens
(smooth muscle actin, keratins 7, 20, AE1/AE3, 34bE12,
Hyal, and HAS) show little antigen decay.
We found that Hyal-1 expression was signiﬁcantly
increased in all pre-neoplastic lesions compared with
malignant lesions. Similar results were previously reported
by Siiskonen et al. (11), who found the proportion of Hyal-
1-positive melanocytic cells was signiﬁcantly reduced
in superﬁcial and deep melanomas and also in lymph
node metastases compared with in situ melanomas. In
our specimens, the staining patterns of Hyal-1 differed
between pre-neoplastic and malignant lesions, and the
intensity of Hyal-1 in epithelial cells progressively de-
creased in malignant lesions compared with pre-neoplastic
lesions. The presence of hyaluronidase in tumor cells has
been shown to increase angiogenesis in vivo (12–14).
Hyaluronan oligosaccharides produced by hyaluronidases
mediate the angiogenic effects (30,31) and may also
activate matrix metalloproteinases, thus enhancing tumor
invasiveness (32). Interestingly, in a mouse model of
prostate cancer, co-expression of a Hyal-1 and a HAS-2
signiﬁcantly increased angiogenesis (33). Upregulation of
Hyal-1 and HAS-1, -2, and -3 in pre-neoplastic lesions
was also observed in the present study.
The amount of hyaluronan seems to be biphasic in
premalignant and malignant pulmonary lesions. First, in
pre-neoplastic lesions, expression of HAS-1-3 in epithelial
cells is greater; at this stage, hyaluronan levels vary
among benign lesions, such as basal cell hyperplasia and
squamous metaplasia. In dysplasia and atypical adenom-
atous hyperplasia, the proportion of HAS-2-positive
epithelial cells is lower than in benign lesions, and at
this state the hyaluronan content is also increased in
cells of benign lesions. This may indicate accumulation
of hyaluronan behind the intact basement membrane
before the invasive phase has occurred. Instead, tumor
cells show markedly reduced hyaluronan levels, which is
associated with increased Hyal-1 expression. In fact,
squamous cell carcinoma originates from the stratiﬁed
epidermis as such. A similar tendency to increase hyalur-
onan staining in premalignant or early-stage malignant
Table 3. Spearman correlation analysis of expression of Hyal-1 and -3 and
HAS-1, -2 and -3 in pre-neoplastic and neoplastic lesion types.
Neoplastic lesions Pre-neoplastic lesions Spearman correlation (P)
Hyal-1 Hyal-1 R=–0.70; P=0.0001
HAS-1 HAS-1 R=–0.30; P=0.03
HAS-3 HAS-3 R=–0.45; P=0.0001
Hyal-1 HAS-1 R=0.40; P=0.0001
Hyal-1 HAS-2 R=0.40; P=0.0001
Hyal-1 HAS-3 R=0.50; P=0.0001
Table 4. Cox proportional hazard model analysis of survival time (chi-square=20.17, P=0.005).
B SE Wald Sig. Exp(B) 95%CI for Exp(B)
Lower Upper
N0 Stage –7.65 3.99 367 0.05 0.00 0.00 1.18
Squamous cell carcinoma –1.21 1.46 0.68 0.40 0.29 0.01 5.25
Pre-neoplastic HYALs
HYAL1 –0.00 0.08 0.01 0.91 0.99 0.83 1.17
HYAL3 –0.07 0.04 2.64 0.10 0.92 0.85 1.01
Pre-neoplastic HAS
HAS1 –0.05 0.04 1.50 0.22 0.94 0.87 1.03
HAS2 –0.03 0.04 0.51 0.47 0.96 0.88 1.05
HAS3 0.17 0.10 3.02 0.04 1.19 0.97 1.44
B: coefﬁcient; SE: standard error; Sig.: signiﬁcance; Exp(B): risk of B coefﬁcient; CI: conﬁdence interval.
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lesions and decreased staining in more advanced tumors
has been reported earlier in squamous cell carcinomas of
oral (34), laryngeal (35), esophageal (23), and skin (36)
epithelium, all originating from stratiﬁed epithelium. Although
adenocarcinoma originates from alveolar epithelial cells and
not from stratiﬁed epithelium as such, a similar tendency to
increased hyaluronan staining in premalignant or early-stage
malignant lesions and decreased staining in more advanced
tumors has been reported in adenocarcinomas of oral (34),
laryngeal (35), esophageal (22), and skin (11) epithelium, all
originating from stratiﬁed epithelium.
Our data show, for the ﬁrst time, the biphasic pattern
of hyaluronan metabolism in lung tumors, and reveals
increased hyaluronan synthesis in premalignant lesions
followed by reduced hyaluronan content in squamous cell
carcinoma and adenocarcinoma as a consequence of
decreased HAS expression and increased degradative
Hyal-1 and -3. Further studies are needed to clarify the
prognostic power of Hyal upregulation and HAS down-
regulation in lung tumors.
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